AngioDynamics, Inc. (NASDAQ:ANGO) Expected to Announce Quarterly Sales of $81.81 Million

Brokerages expect AngioDynamics, Inc. (NASDAQ:ANGOGet Rating) to report sales of $81.81 million for the current fiscal quarter, Zacks reports. Three analysts have made estimates for AngioDynamics’ earnings. The highest sales estimate is $82.00 million and the lowest is $81.60 million. AngioDynamics reported sales of $76.84 million in the same quarter last year, which would suggest a positive year over year growth rate of 6.5%. The business is expected to report its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that AngioDynamics will report full-year sales of $313.37 million for the current fiscal year, with estimates ranging from $313.00 million to $313.80 million. For the next year, analysts anticipate that the company will report sales of $336.89 million, with estimates ranging from $335.28 million to $338.30 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow AngioDynamics.

AngioDynamics (NASDAQ:ANGOGet Rating) last released its quarterly earnings data on Thursday, April 7th. The medical instruments supplier reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.04. The firm had revenue of $74.00 million during the quarter, compared to analyst estimates of $76.32 million. AngioDynamics had a negative return on equity of 0.12% and a negative net margin of 12.99%. The business’s quarterly revenue was up 3.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.02 earnings per share.

ANGO has been the subject of a number of research analyst reports. StockNews.com initiated coverage on AngioDynamics in a research note on Thursday, March 31st. They issued a “hold” rating for the company. Zacks Investment Research lowered AngioDynamics from a “hold” rating to a “strong sell” rating and set a $21.00 price target for the company. in a research note on Tuesday, March 8th. Finally, Canaccord Genuity Group raised their price target on AngioDynamics from $34.00 to $40.00 in a research note on Friday. One research analyst has rated the stock with a sell rating, two have issued a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $32.50.

A number of institutional investors have recently made changes to their positions in the business. Polar Capital Holdings Plc increased its holdings in shares of AngioDynamics by 1,257.7% during the third quarter. Polar Capital Holdings Plc now owns 1,325,508 shares of the medical instruments supplier’s stock valued at $34,384,000 after acquiring an additional 1,227,882 shares in the last quarter. Allspring Global Investments Holdings LLC bought a new position in shares of AngioDynamics during the fourth quarter valued at $12,093,000. Point72 Asset Management L.P. increased its holdings in shares of AngioDynamics by 117.7% during the fourth quarter. Point72 Asset Management L.P. now owns 778,354 shares of the medical instruments supplier’s stock valued at $21,467,000 after acquiring an additional 420,822 shares in the last quarter. Loomis Sayles & Co. L P increased its holdings in shares of AngioDynamics by 40.5% during the fourth quarter. Loomis Sayles & Co. L P now owns 1,028,178 shares of the medical instruments supplier’s stock valued at $28,357,000 after acquiring an additional 296,312 shares in the last quarter. Finally, Soleus Capital Management L.P. increased its holdings in shares of AngioDynamics by 112.5% during the fourth quarter. Soleus Capital Management L.P. now owns 515,450 shares of the medical instruments supplier’s stock valued at $14,216,000 after acquiring an additional 272,925 shares in the last quarter. 94.11% of the stock is owned by institutional investors and hedge funds.

NASDAQ:ANGO opened at $22.51 on Tuesday. The firm has a market cap of $871.52 million, a PE ratio of -21.85 and a beta of 0.93. AngioDynamics has a fifty-two week low of $20.03 and a fifty-two week high of $32.00. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.61 and a current ratio of 2.59. The business has a 50 day moving average price of $22.44 and a 200-day moving average price of $24.95.

AngioDynamics Company Profile (Get Rating)

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally.

Featured Articles

Get a free copy of the Zacks research report on AngioDynamics (ANGO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.